0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Siglec-3

Siglec-3

Siglec-3 Molecule Information

Name:Myeloid cell surface antigen CD33
Target Synonym:Sialic acid-binding Ig-like lectin 3;Myeloid cell surface antigen CD33;Siglec-3;gp67;CD33;CD_antigen=CD33;SIGLEC3
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:29
Lastest Research Phase:Approved

Siglec-3 Protein Product ListCompare or Buy

Siglec-3 Molecule Synonym Name

CD33,SIGLEC3,gp67

Siglec-3 Molecule Background

Myeloid cell surface antigen CD33 is also known as SIGLEC3, Siglecs (sialic acid binding Ig­like lectins) and GP67, is a single-pass type I membrane protein which belongs to the immunoglobulin superfamily and SIGLEC (sialic acid binding Ig-like lectin) family. Human CD33 / Siglec-3 cDNA encodes a 364 amino acid (aa) polypeptide with a hydrophobic signal peptide, an N-­terminal Ig-­like V­-type domain, one Ig­-like C2-­type domains, a transmembrane region and a cytoplasmic tail. CD33 / Siglec-3 usually considered myeloid-specific, but it can also be found on some lymphoid cells. In the immune response, CD33 / Siglec-3 may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules. CD33 / Siglec-3 induces apoptosis in acute myeloid leukemia.

Siglec-3 References

Siglec-3 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Gemtuzumab ozogamicin CMA-676; CL-555201; CDP-771; WAY-CMA-676; hP67.6-calicheamicin,CMA676,CL555201 Approved Pfizer, UCB MYLOTARG fda Acute myeloid Leukemia (AML) WYETH PHARMS INC 2000-05-17 Acute myeloid Leukemia (AML) Details

Siglec-3 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Lintuzumab Ac-225 (Actinium Pharmaceuticals) 225Ac-HuM-195; AC225-MOAB-M195; HuM195-Ac-225 Phase Ⅱ PDL BioPharma, Actinium Pharmaceuticals, Memorial Sloan-Kettering Cancer Center, University of Texas M. D. Anderson Cancer Center Acute myeloid Leukemia (AML) Details
HuM195-gelonin immunotoxin Phase Ⅰ Memorial Sloan-Kettering Cancer Center, Banner MD Anderson Cancer Center Myelodysplastic syndrome (MDS), Acute myeloid Leukemia (AML), Chronic myeloid leukemia (CML ) Details
Anti-CD33/anti-FcgammaRI bispecific antibody (UCSD) Phase Ⅰ University of California San Diego Acute myeloid Leukemia (AML) Details
AVE-9633 AVE-9633 Phase Ⅰ ImmunoGen, Sanofi Acute myeloid Leukemia (AML) Details
Lintuzumab-gelonin conjugate Phase Ⅰ University of Texas M. D. Anderson Cancer Center Myelodysplastic syndrome (MDS), Acute myeloid Leukemia (AML), Chronic myeloid leukemia (CML ) Details
OXS-3550 GTB-3550; OXIS-3550; OXS-3550; OXS-3550-TriKE Phase Ⅱ University of Minnesota, Oxis Biotech Myelodysplastic syndrome (MDS), Aggressive systemic mastocytosis (ASM), Acute myeloid Leukemia (AML) Details
OXS-C3550 OXS-3350; OXS-C3550 Preclinical University of Minnesota, GT Biopharma Acute myeloid Leukemia (AML) Details
Oncolysin M Oncolysin-M Phase Ⅰ ImmunoGen, Dana-Farber Cancer Institute Acute myeloid Leukemia (AML) Details
Lintuzumab HuM-195; SGN-33 Phase Ⅲ PDL BioPharma, Seattle Genetics Myelodysplastic syndrome (MDS), Leukemia, Acute granulocytic leukemia Details
CLL-1-CD33 cCART cell therapy (iCell Gene Therapeutics) CLL-1-CD33 cCAR,CLL-1 CD33 cCAR Phase Ⅰ iCell Gene Therapeutics Acute myeloid Leukemia (AML) Details
ICG-136 ICG-136 Phase Ⅰ iCell Gene Therapeutics, Chengdu Military General Hospital Acute myeloid Leukemia (AML) Details
AMG-673 AMG-673; AMG673 Phase Ⅰ Amgen Acute myeloid Leukemia (AML) Details
Anti-CD33 chimeric antigen receptor T cell therapy (Intrexon/ZIOPHARM Oncology) Phase Ⅰ Ziopharm Oncology, Intrexon Corporation Acute myeloid Leukemia (AML) Details
CLL1-CD33 cCART cell therapy (iCell Gene Therapeutics) CLL1-CD33-cCAR Phase Ⅰ iCell Gene Therapeutics, Chengdu Military General Hospital Acute myeloid Leukemia (AML) Details
M195-Y-90 Phase Ⅰ Nonindustrial source Acute myeloid Leukemia (AML), Cancer Details
M-195 Phase Ⅲ Nonindustrial source, PDL BioPharma, Akzo Nobel Myelodysplastic syndrome (MDS), Myeloid leukemia, Acute myeloid Leukemia (AML), Acute promyelocytic leukemia (APL) Details
Anti-CD33 CAR T cell therapy (Wuhan Bio-Raid) Phase Not Specified Wuhan Bio-Raid Biotechnology Acute myeloid Leukemia (AML) Details
JNJ-67571244 JNJ-67571244; JNJ-1244 Phase Ⅰ Johnson & Johnson Myelodysplastic syndrome (MDS), Acute myeloid Leukemia (AML) Details
IMGN-779 IMGN-779 Phase Ⅰ ImmunoGen Myelodysplastic syndrome (MDS), Acute myeloid Leukemia (AML) Details
GEM-333 GEM-333 Phase Ⅰ GEMoaB Monoconals Acute myeloid Leukemia (AML) Details
Lintuzumab Bi-213 Phase Ⅱ PDL BioPharma, Actinium Pharmaceuticals Acute myeloid Leukemia (AML) Details
Vadastuximab talirine 33-A; SGN-CD33A Phase Ⅲ Seattle Genetics Myelodysplastic syndrome (MDS), Acute myeloid Leukemia (AML) Details
AMV-564 T-564; AMV-564 Phase Ⅰ Amphivena Therapeutics Myelodysplastic syndrome (MDS), Acute myeloid Leukemia (AML) Details
Anti-CD33 CAR-NK cell therapy (PersonGen Biomedicine) Phase Ⅱ PersonGen Biomedicine Acute myeloid Leukemia (AML) Details
BI-836858 BI-836858,BI 836858,BI836858 Phase Ⅱ Boehringer Ingelheim Myelodysplastic syndrome (MDS), Acute myeloid Leukemia (AML) Details
AFM-24 AFM-12; AFM-18; AFM-20; AFM-21; AFM-22; AFM-24; AFM-24+; AFM-26; AFM-26+ Preclinical Affimed, Amphivena Therapeutics Colorectal cancer, Lung cancer, Acute myeloid Leukemia (AML), Head and neck cancer, Cancer Details
AL-003 AL-003 Phase Ⅰ Abbvie, Alector Alzheimer's disease (AD) Details
CART-33 (Chinese PLA General Hospital) Phase Ⅱ General Hospital of the People's Liberation Army Acute myeloid Leukemia (AML) Details
AMG-330 AMG-330; MT-114  Phase Ⅰ Amgen Acute myeloid Leukemia (AML) Details

This web search service is supported by Google Inc.

totop